美罗培南在成人重症感染患者中的群体药动学研究进展

打开文本图片集

中图分类号R969.1 文献标志码A 文章编号 1001-0408（2025）22-2873-06

DOI 10.6039/j.issn.1001-0408.2025.22.21

ABSTRACTMeropenem（MEM）isoneof theimportant drugs forthe treatmentof severe infections，butthe standard doseis oftendifculttoachieveanefectivetherapeuticconcentrationtarget.Thisarticlereviewstherelatedstudiesonthepopulation pharmacokinetics of MEMin patients with severe infection.It is found that the apparent volumeof distribution（ Vd ）and clearance rate are the most important factors affecting the dose adjustment，and the factors affecting Vd include serum albumin，age，overall weight，shock status，andchest/abdomen/cerebrospinalfluiddrainage.Themain factorsafectingtheclearanceratewererenal function，renalreplacementtherapytreatmentmodeandcombination therapyForadult patients withsevereinfections inChina， MEMis recommendedtobeadministered inanindividualized manerbasedonglomerularfiltrationrate，withadosagerangeof 500to 1500mg given every 4 to 6 hours，and prolonged infusion is preferred.When the minimum inhibitory concentration （MIC） of the pathogenic bacteria reaches 64mg/L ，therapeutic drug monitoringisrequired.For therapeutic efficacy，itisessential to ensurethat thetrough concentration remainsabove theMIC；to prevent drugresistance，it shouldbe maintained above 4× MIC. Regarding safety，it isrecommended that the upper limit of the trough concentration be 32mg/L ，and blood sampling for monitoring can be conducted as early as after1 to 2 doses of administration.

KEYWORDS severe infection；meropenem；population pharmacokinetics；drug administration plan

重症感染是指由感染引起的全身性炎症反应，并导致器官功能衰竭的临床综合征，若未得到有效控制，可进展为脓毒症。（剩余12521字）